ABRDN Physical Gold Shares ETF vs Zimmer Biomet Holdings Inc — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.94 (market cap $7.03B), while Zimmer Biomet Holdings Inc trades at $89.33 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.4× ABRDN Physical Gold Shares ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ABRDN Physical Gold Shares ETF for 57 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SGOL | ZBH | |
|---|---|---|
Market Cap | $7.03B | $16.95B |
Volume | 2,350,550 | 2,505,240 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $103.98 |
52-Week Low | $37.54 | $79.58 |
Typical Hold Time | 57 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
SGOL trades at $39.94, up 2.36% with a bearish technical outlook showing 17 sell signals versus 2 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent softer inflation data provided some support. Moving averages indicate strong bearish momentum while oscillators remain neutral, suggesting potential consolidation near current levels.
The outlook remains cautious with technical indicators favoring downside momentum, though oversold conditions could provide near-term support. Key risks include persistent inflation concerns and Fed policy uncertainty, while potential catalysts include geopolitical tensions and sustained gold demand from China. Investors should monitor Treasury yield movements and inflation data for directional cues.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →